# Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

> **NCT03589950** · PHASE2 · UNKNOWN · sponsor: **The First People's Hospital of Lianyungang** · enrollment: 60 (estimated)

## Conditions studied

- Lung Neoplasms
- Docetaxel
- Pemetrexed
- S-1
- Anlotinib

## Interventions

- **DRUG:** anlotinib plus chemotherapy
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT03589950
- **Lead sponsor:** The First People's Hospital of Lianyungang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2020-08-01
- **Final completion:** 2021-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2018-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589950, "Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03589950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*